AAOpt 2024: Simplifying genetic testing

News
Video

Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, details the ease of genetic testing when diagnosing patients or reassessing a patient's diagnosis.

Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, discusses one of his presentations, "Suprachoroidal Delivery of Investigational ABBV-RGX-314 Gene Therapy for Diabetic Retinopathy: The Phase II ALTITUDE Study," which he gave alongside Roya Attar, OD, MBA, DHA at the AAOpt 2024 conference.

Video transcript:

Editor's note: The below transcript has been lightly edited for clarity.

Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO:

Hello everybody. This is Mohammad Rafieetary. I'm an optometrist at the Charles Retina Institute in the Tennessee, Arkansas, Mississippi area. I had a second presentation on inherited retinal disorders and why genetic testing is important. And I was accompanied by a colleague, Dr Roya Attar. She's at the University of Mississippi Medical Center, Department of Ophthalmology in Jackson, Mississippi. We talked about genetic variation. We talked about particularly epigenetic variation. You know, if you think about a condition, for instance, macular degeneration, that's not a Mendelian disease, but has a genetic component to it. Why do we talk about smoking? Because smoking affects the epigenetics. These are situations where your DNA changes without your DNA sequence chang[ing], and you affect the body's behavior, your protein productions, your normal cell function by either what you inherited from your relatives or by what you're doing to your own. So I went through a number of cases. [Attar] described a lot number of situations as to, why is it to do genetic testing. You know, we have all sorts of imaging. We have functional testing, we have electrodiagnostic, we do laboratory testing for patients who are at risk for infectious disease. Yet, we have another thing, genetic testing, when things don't make sense.
I showed a case, for instance, that the patient, for a number of years, was diagnosed with retinitis pigmentosa, but she had also been on Plaquenil for a number of years. When I did genetic testing on her, she had no genetic predisposition or variation for retinitis pigmentosa. So her retinal findings were associated with retinal toxicity from hydroxychloroquine. So again, we now have an easier way to do genetic testing by a simple cheek swab and filling out some forms and sending it to laboratories where they can give us results, and we look at those results. Does this make sense? Does the clinical presentation, history of this patient, all the testing we do and this other data, do they all go together to make the correct diagnosis?

Recent Videos
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
© 2024 MJH Life Sciences

All rights reserved.